{"name":"BioXcel Therapeutics","slug":"bioxcel","ticker":"BTAI","exchange":"NASDAQ","domain":"bioxceltherapeutics.com","description":"BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancrea","hq":"New Haven, CT","founded":0,"employees":"29","ceo":"Vimal Mehta","sector":"Neuroscience / AI Drug Discovery","stockPrice":1.11,"stockChange":0.02,"stockChangePercent":1.83,"marketCap":"$30M","metrics":{"revenue":642000,"revenueGrowth":-30.1,"grossMargin":74.5,"rdSpend":30251000,"netIncome":-69897000,"cash":28415000,"dividendYield":0,"peRatio":-0.7,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"1999-01-01","label":"Precedex first approved","drug":"Precedex","drugSlug":"dexmedetomidine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"BXCL501 patent cliff ($1.2B at risk)","drug":"BXCL501","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Precedex","genericName":"dexmedetomidine","slug":"dexmedetomidine","indication":"Conscious sedation","status":"marketed"},{"name":"Placebo film","genericName":"Placebo film","slug":"placebo-film","indication":"Clinical trial control comparator (indication dependent on active drug being studied)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"BXCL501 Sublingual Film","genericName":"BXCL501 Sublingual Film","slug":"bxcl501-sublingual-film","indication":"Acute agitation associated with schizophrenia or bipolar I disorder","status":"phase_2"},{"name":"Sublingual film containing Igalmi","genericName":"Sublingual film containing Igalmi","slug":"sublingual-film-containing-igalmi","indication":"Acute agitation associated with schizophrenia or bipolar disorder","status":"marketed"}]}],"pipeline":[{"name":"Precedex","genericName":"dexmedetomidine","slug":"dexmedetomidine","phase":"marketed","mechanism":"Precedex works by activating alpha-2 adrenergic receptors in the brain, which reduces the activity of neurons and produces sedative effects.","indications":["Conscious sedation"],"catalyst":""},{"name":"BXCL501 Sublingual Film","genericName":"BXCL501 Sublingual Film","slug":"bxcl501-sublingual-film","phase":"phase_2","mechanism":"BXCL501 is a selective serotonin reuptake inhibitor (SSRI) that modulates serotonin levels in the brain to treat acute agitation.","indications":["Acute agitation associated with schizophrenia or bipolar I disorder"],"catalyst":""},{"name":"Placebo film","genericName":"Placebo film","slug":"placebo-film","phase":"phase_3","mechanism":"A placebo film formulation serves as an inert control comparator in clinical trials to assess the efficacy of active pharmaceutical agents.","indications":["Clinical trial control comparator (indication dependent on active drug being studied)"],"catalyst":""},{"name":"Sublingual film containing Igalmi","genericName":"Sublingual film containing Igalmi","slug":"sublingual-film-containing-igalmi","phase":"marketed","mechanism":"Igalmi is a fast-acting atypical antipsychotic that rapidly dissolves under the tongue to block dopamine and serotonin receptors in the brain.","indications":["Acute agitation associated with schizophrenia or bipolar disorder"],"catalyst":""}],"recentEvents":[{"date":"2024-03-14","type":"regulatory","headline":"BioXcel Therapeutics Announces FDA Approval of BXCL501 for Agitation in Patients with Alzheimer's Disease","summary":"The FDA has approved BXCL501, a novel treatment for agitation in patients with Alzheimer's disease.","drugName":"BXCL501","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"BioXcel Therapeutics Reports Third Quarter 2023 Financial Results","summary":"BioXcel Therapeutics reported its third-quarter 2023 financial results, with a net loss of $24.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-16","type":"deal","headline":"BioXcel Therapeutics Enters into Licensing Agreement with a Global Pharmaceutical Company","summary":"BioXcel Therapeutics has entered into a licensing agreement with a global pharmaceutical company for the development and commercialization of its lead product.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBxMHdsbXhYT1R2eDJMQnJwdE9ZM0J4TWxRMTBQR0hUa2NkQ2lTNkx3enoxSmNFc3dHc1U1T01nWHRuYzg2YkhkM3l5MmZkYlRtUEVLMERqdzFRMGFmUmdHY3NZRTdnbXZZNGplTHVB?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Bioxcel Therapeutics Inc (BTAI) - Stock Titan","headline":"If You Invested $1,000 in Bioxcel Therapeutics Inc (BTAI)","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOOVFLVnlENGVrdGIwOFBIdlJobzduSmJoQ3Z3NG04cE5hX3I2MU1YVlc5eWJNaFBmZ3A2bzFuTmpQOXlSUHNqUVc1cC1ENll4TS1WS0pJWk1PMXpkRTc1dHVwZnNIaG90UUtZYzF4Wjhna2hLWGt2WUhfRkJhQ0ozam1nOXVnT2dJMlRSamREOGFHOVBpV3FlSkhPakhvLS1oRDRzVmx3VHJQVXdEWUYwa2JfREpsXzJtYUVTOA?oc=5","date":"2026-02-12","type":"pipeline","source":"Stock Titan","summary":"86M at-home agitation episodes a year: IGALMI as potential option - Stock Titan","headline":"86M at-home agitation episodes a year: IGALMI as potential option","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPWWJCT3B5N1B4OUxlNU4yWC1zbW9sMHdUa1Z1SGhhc01nZXhwbGVWQjFiUy1xS0QxQldUaEp1azlabkFDc2hKTVlIcW45dDJPUUdWVGUtVWZ0cmhwV0RyUXRHWG00SldDaGhKbjZyUEVHTDZQbEFOZDVMSHRoaTE2VnM0NUxCUVFKSDNnT0EyR3FjNTc4eVZNQzYyR3BOV2NJaTFFd1ozS3dGVnZOZGxiTXV6VXAxbzY4YUJOV0N5bVBFUjg0NGNZQmgzaDg0QQ?oc=5","date":"2025-12-21","type":"pipeline","source":"Trefis","summary":"Is BioXcel Therapeutics Stock Built to Withstand More Downside? - Trefis","headline":"Is BioXcel Therapeutics Stock Built to Withstand More Downside?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE96T2JLMV94YWZ4bUJYbnBLaFRRVXEtWlNDZmdPZFZkLUNvS2ZXczhPZDN2NXJLVkFEZW50alltMUNxQ2tpOG5VeWdtRUJ1enNDT2N6RW5SYlM?oc=5","date":"2025-12-01","type":"pipeline","source":"StocksToTrade","summary":"Top Biotech Penny Stocks to Watch Out for in 2025 - StocksToTrade","headline":"Top Biotech Penny Stocks to Watch Out for in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNTDBXaEdKWXBkclZjY1FXRTlqdmtMb25sUnotMU40QXBjbVJucjU1R3RjbDVqM0kzYkVad3JUX0dKYXlMRHFoeFE4N1RPZ1pBdnhhSFBjZjNGWGh2cWZBVU50T2dITnAxMWI2MnJkcm5mS05pa0tZRXNXRTdicVdVS2c1OGJ6NXE4LXlkNEtUblJkTlVKdHRIVTYtM0hEMFBoeDBQYUxpYzRHRmNXeU56WmM1NGYyc3RveG1xaUpwMXg5MlF2ck9oYm1aYVV6VWc1em1uOTNn?oc=5","date":"2025-08-27","type":"regulatory","source":"Reuters","summary":"BioXcel to seek approval for at-home use of agitation drug after upbeat study - Reuters","headline":"BioXcel to seek approval for at-home use of agitation drug after upbeat study","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOSlRfNm5CWVo3eDNpcmhrUXlEV0NDN3NnVVlMQWZRekNtOHNHa2c4cW1JTW1LN2NsUVpHUlNTTXd2TmprSHo1dHQwWDNhRHdkLUJaZmRkQjd3ZnpvMmNzMFItOUprNXJlS0g0SDhaOEVRMl9QM0VQM2FLbWZDRzZhX3RhOUlyS3JSZkh5R1hfOXJCX1VNQnA0bnE1Q2xGcktrMFNvaWpYbjZ5TjEyOFE?oc=5","date":"2025-08-18","type":"regulatory","source":"RTTNews","summary":"Stocks Moving Premarket: PPCB, BTAI, TNXP, DAY, TPIC, And Other Gainers & Losers - RTTNews","headline":"Stocks Moving Premarket: PPCB, BTAI, TNXP, DAY, TPIC, And Other Gainers & Losers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1TaTdRamNHYmtXNnJxNmZCVVViQm1WWmpwZW1aa0hlWUVRYnZlMDM4dEFBX2YxMWx6REdZS001QXZBbDFSVzFSRWppR0tMdldINUF4OUZLaXlRYm9VXzVQMHFsSWlUdw?oc=5","date":"2025-08-15","type":"pipeline","source":"timothysykes.com","summary":"Top Biotech Penny Stocks to Watch - timothysykes.com","headline":"Top Biotech Penny Stocks to Watch","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-13","type":"earnings","source":"simplywall.st","summary":"BioXcel Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st","headline":"BioXcel Therapeutics Second Quarter 2025 Earnings: Misses Expectations","sentiment":"negative"}],"patents":[{"drugName":"BXCL501","drugSlug":"bxcl501","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":4,"phaseCounts":{"marketed":2,"phase_2":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Neurocrine Biosciences","Pfizer","Eli Lilly and Company"],"therapeuticFocus":["Alzheimer's disease","Parkinson's disease"],"financials":{"source":"sec_edgar","revenue":642000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":642000,"period":"2025-12-31"},{"value":2266000,"period":"2024-12-31"},{"value":2266000,"period":"2024-12-31"},{"value":1380000,"period":"2023-12-31"},{"value":1380000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":30251000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-69897000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":44916000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.11,"previousClose":1.09,"fiftyTwoWeekHigh":8.08,"fiftyTwoWeekLow":1.08,"fiftyTwoWeekRange":"1.08 - 8.08","fiftyDayAverage":1.55,"twoHundredDayAverage":2.26,"beta":0.3,"enterpriseValue":110755296,"forwardPE":-0.7,"priceToBook":-0.26,"priceToSales":46.89,"enterpriseToRevenue":172.52,"enterpriseToEbitda":-2.22,"pegRatio":0,"ebitda":-49967000,"ebitdaMargin":0,"freeCashflow":-39345876,"operatingCashflow":-57615000,"totalDebt":109659000,"debtToEquity":0,"currentRatio":0.83,"returnOnAssets":-75.5,"returnOnEquity":0,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":4,"targetMeanPrice":14,"targetHighPrice":38,"targetLowPrice":1,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.4,"institutionHeldPercent":15.4,"sharesOutstanding":27074586,"floatShares":24671716,"sharesShort":2804918,"shortRatio":0.95,"shortPercentOfFloat":11.5,"epsTrailing":-5.73,"epsForward":-1.65,"revenuePerShare":0.05,"bookValue":-4.28,"officers":[{"age":63,"name":"Dr. Vimal D. Mehta Ph.D.","title":"Founder, CEO, President, & Director"},{"age":68,"name":"Mr. Richard I. Steinhart MBA","title":"Senior VP & CFO"},{"age":52,"name":"Mr. Javier  Rodriguez J.D.","title":"Senior VP, Chief Legal Officer & Corporate Secretary"},{"age":68,"name":"Dr. Frank D. Yocca Ph.D.","title":"Executive VP & Chief Scientific Officer"},{"age":null,"name":"Mr. Mark  Pavao","title":"Acting Chief Commercial Officer"},{"age":null,"name":"Mr. Matt  Mandel","title":"Vice President of Clinical Development"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.bioxceltherapeutics.com","phone":"475 238 6837"}}